Hims vs Ro vs Noom: Differences in Mechanism, Evidence, and Expected Results
None of the three has a mechanism of its own. Weight change comes from the pharmacology of the molecule and from sustained changes in eating behavior, and all three arrange access to the same drug classes. The difference is which lever each service is built around: one sells behavior change with clinical services attached, the other two sell supervised medication access.
The pharmacology belongs to the molecule
Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both the GIP and GLP-1 receptors. Both slow gastric emptying, act on central appetite regulation, and reduce energy intake, and neither behaves differently according to which website arranged the prescription. An orally administered small-molecule GLP-1 receptor agonist, orforglipron, has since been approved for weight reduction under the brand name Foundayo, which widens what supervised medication access can mean without changing this principle.
This is the single most misread part of provider comparisons. A platform can influence whether a patient starts, whether the dose reaches a therapeutic level, and whether the patient is still taking it in month nine. It cannot alter what the drug does at a given dose in a given person.
It is worth remembering that most of these companies are not single-product operations. Hims and Hers and Ro run men’s health, dermatology and mental health lines beside their weight programs, and providers such as HealthRX keep dedicated clinical pages for areas like ED treatment next to their metabolic material, whereas Henry Meds concentrates on GLP-1 access alone. Breadth is a convenience rather than a measure of quality, so the evidence for each product has to be read on its own terms instead of inferred from the size of the menu.
What the drug trials measured, and what they did not
The registration trial of once-weekly semaglutide in adults with overweight or obesity reported mean body weight reduction of roughly 15 percent over 68 weeks. A separate trial of tirzepatide reported roughly 21 percent at the highest dose over 72 weeks. Those are two different studies with different populations and durations, so quoting them side by side indicates direction rather than a measured gap. A later randomized trial did compare the two agents directly in adults with obesity and reported greater average reduction with tirzepatide, and that is the study to cite when a head-to-head claim is needed.
What none of those trials evaluated is a vendor. Participants received structured lifestyle counseling as part of the protocol, dosing was supervised, and adherence was tracked. Trial percentages therefore describe close to the best case for the molecule under supervision, which is why they belong in a comparison of drugs rather than a comparison of subscriptions.
The behavioral evidence is a separate literature
Structured behavior change has its own trial record, and it predates the current medications by decades. The Diabetes Prevention Program showed that an intensive lifestyle intervention reduced progression to type 2 diabetes more than metformin did in adults at high risk. The Look AHEAD trial delivered intensive lifestyle intervention in type 2 diabetes and produced sustained weight loss and fitness gains without reducing cardiovascular events over a median of roughly ten years. Behavioral programs work, and they work on different endpoints than the drugs do.
One trial bridges the two literatures directly. In a randomized study of subcutaneous semaglutide given as an adjunct to intensive behavioral therapy, both arms received the behavioral program and the medication arm lost substantially more weight. That design is the closest published analogue to what a bundled program is selling, and it supports the drug as the larger contributor while showing the behavioral layer is not decorative.
| Question | Behavior-first program with clinical services | Medication-first telehealth platform |
|---|---|---|
| What is the core product | A curriculum and coaching, with prescribing added | Supervised prescribing, with support added |
| Which lever it is designed to move | Eating behavior, tracking, adherence habits | Access, dose escalation, refill continuity |
| Best supporting evidence | Lifestyle intervention trials, plus drug-with-behavioral-therapy trials | Drug registration and head-to-head trials |
| Where results are usually lost | Program attrition before the medication takes effect | Stalled titration or a lapse in supply |
| What it cannot change | The pharmacology at a given dose | Whether eating patterns hold after stopping |
| Signal to check before starting | Whether medication is included or a separate charge | Whether the pathway is brand or compounded |
Why real-world results sit below trial numbers
Observational data from routine care consistently reports smaller average weight reduction than the trials. Analyses of tirzepatide use among people without type 2 diabetes in large claims and records databases show real-world effectiveness below trial figures, and cohort work on GLP-1 receptor agonists shows that a substantial share of patients never reach or never sustain the higher maintenance doses. Persistence, not pharmacology, is the usual explanation.
That is the honest case for a behavior-focused bundle, and also the honest case against overpaying for one. Structure helps some people stay on treatment. Nobody has shown that any specific commercial coaching product produces the effect measured in the intensive behavioral therapy arms of the published trials, which were delivered by trained interventionists on a fixed schedule.
The pathway changes which evidence applies
Trial results attach to the studied product. Compounded semaglutide and compounded tirzepatide are pharmacy preparations that the FDA has not reviewed for safety, effectiveness or manufacturing quality, and they are not FDA-approved. Extrapolating a published percentage to a compounded preparation assumes equivalence that has not been established for that preparation.
That is an argument for knowing the pathway, not for avoiding compounded care outright, which operates under a defined legal framework with licensed prescribers and licensed pharmacies. Providers vary in how plainly they state it. Ro’s published weight materials describe routing to approved GLP-1 products on a cash basis when insurance does not cover them, cash-pay compounded programs such as Henry Meds and formblends.com state the compounded pathway alongside the price, and a bundled program may include either depending on the product selected. Reading that one detail tells a reader which trial evidence is relevant to what they are about to take.
Frequently asked questions
Can a coaching program improve on the drug’s trial results?
There is no evidence that it exceeds them. The relevant trial gave both arms intensive behavioral therapy and found the medication arm lost considerably more weight. Behavioral support plausibly protects adherence and dose escalation, which matters in routine care, but the ceiling in that study was set by the drug.
Is tirzepatide better than semaglutide for everyone?
A direct randomized comparison in adults with obesity reported greater average weight reduction with tirzepatide. Averages are not individuals, tolerability differs, and cost, supply and comorbidities all enter the decision. The comparison also says nothing about which platform arranges the prescription.
Why do real-world results look weaker than the headlines?
Mostly because of dose and duration. Trial participants were escalated on protocol and followed for more than a year. Routine-care cohorts show many patients stopping early or remaining on lower doses, and observed weight change tracks that. The molecule performs as studied when the regimen is actually reached.
Does an approved oral option change the comparison?
It broadens it. An approved oral small-molecule GLP-1 receptor agonist removes injection reluctance as a barrier for some patients and creates a new pricing tier. It does not change how any of these services is structured, and availability through any given platform has to be checked rather than assumed.
